SITC

Bexion Pharmaceuticals, Inc. Appoints Dr. Tariq Arshad as Chief Medical Officer

Retrieved on: 
Wednesday, February 28, 2024
Biotechnology, CIPN, MD, ASCO, Strategic planning, SITC, Clinical research, Chemotherapy-induced peripheral neuropathy, AACR, MBA, Society, Immunology, Patient, Immunotherapy, Head, Medical device

COVINGTON, Ky., Feb. 28, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced the appointment of Tariq Arshad, MD, MBA as Chief Medical Officer.

Key Points: 
  • COVINGTON, Ky., Feb. 28, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced the appointment of Tariq Arshad, MD, MBA as Chief Medical Officer.
  • Dr. Arshad is an oncologist with more than 25 years of experience and a successful track record of strategic planning, clinical development, and commercialization.
  • "We are thrilled to appoint Dr. Arshad as Bexion's Chief Medical Officer," said Scott Shively, Bexion's Chief Executive Officer.
  • Dr. Arshad previously led medical strategies for blockbuster biologic therapies approved for clinical use in major immunology indications and other groundbreaking therapies as Head of Medical Affairs for Immunology at Sanofi, and he served as Chief Medical Officer and Head of Clinical Research at Humanigen, developing novel immune-oncology therapies.

Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update

Retrieved on: 
Wednesday, February 14, 2024
IPR, Research, CMO, Decompression (diving), PR, Society, Bifunctional, MNP, PRS, Bank statement, Melanoma, OTCQB, ICI, Toronto Stock Exchange, SITC, CBV, Annual general meeting, European Medicines Agency, Partnership, BTD, Highlight, AACR, Conference, Safety, Clinical trial, Survival, Neurology, CFO, EMA, Enzyme, MD, ECA, FDA, TSX, Cancer, EDGAR, Pembrolizumab, Response, MDNA, SNO, Patient, Pharmaceutical industry

Today, the Company reports promising clinical data from the on-going monotherapy escalation and expansion arms of the ABILITY-1 study.

Key Points: 
  • Today, the Company reports promising clinical data from the on-going monotherapy escalation and expansion arms of the ABILITY-1 study.
  • Clinical update from the combination arm of the ABILITY-1 study evaluating MDNA11 in with KEYTRUDA® expected in H1 and H2 of 2024.
  • Research and development expenses of $3.0 million were incurred during the quarter ended December 31, 2023, compared with $2.9 million incurred in the quarter ended December 31, 2022.
  • General and administrative expenses of $1.8 million were incurred during the quarter ended December 31, 2023, compared with $2.0 million during the quarter ended December 31, 2022.

Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024

Retrieved on: 
Monday, February 12, 2024
Nitrogen oxide, Conference call, Nitric oxide, Research, PMA, B cell, Hebrew University of Jerusalem, FDA, Clinical research associate, SITC, NOS1, UNO, Pneumonia, Season, ASD, Society, Conference, Commercial, HUJI, Phenotype, Patient, DSM-IV codes, Immunotherapy, VCAP, NTM, Fiscal year, Nontuberculous mycobacteria

“In the third quarter of fiscal year 2024, we reported solid sequential revenue growth of more than 60% compared with the second quarter.

Key Points: 
  • “In the third quarter of fiscal year 2024, we reported solid sequential revenue growth of more than 60% compared with the second quarter.
  • This increasing demand for our current LungFit PH system was seen even as we prepared to launch a key software update.
  • As our inventory of upgraded LungFit PH grows, we expect to be able to meet accelerating demand over the next several quarters.
  • General and administrative expenses for the three months ended December 31, 2023 and December 31, 2022 were $9.8 million and $8.9 million, respectively.

Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, February 8, 2024
Carcinoma, Neoplasm, Melanoma, NMSC, Merkel-cell carcinoma, REPL, Angiosarcoma, SITC, PFS, Clinical trial, Research, RECIST, Society, Hercules, Patient, CSCC, Type, FDA, Marketing, Investment, RP1, Food, MCC, Immunotherapy, Skin, Nivolumab, Uveal melanoma, Annual general meeting, BLA, RP2, Pharmaceutical industry

WOBURN, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended December 31, 2023, and provided a business update.

Key Points: 
  • WOBURN, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended December 31, 2023, and provided a business update.
  • We plan to submit a BLA for the treatment of patients with anti-PD1 failed melanoma in 2H 2024.
  • Selling, general and administrative expenses included $4.5 million in stock-based compensation expenses for the third quarter ended December 31, 2023.
  • Net Loss: Net loss was $51.1 million for the third quarter ended December 31, 2023, as compared to a net loss of $39.7 million for the third quarter ended December 31, 2022.

Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors

Retrieved on: 
Thursday, February 8, 2024
Standard of care, Immunotherapy, Amgen, Prostate cancer, Research, SITC, Society, Patient, ESSA, FDA, Publication, Biomarker, Doctor of Philosophy, NanoString Technologies, Therapy, Drug development, Biogen, Journal, University, Puma Biotechnology

Dr. Cesano succeeds Dr. Kenneth Hillan, who will step down effective today after a successful 7-year tenure as a director of Zymeworks.

Key Points: 
  • Dr. Cesano succeeds Dr. Kenneth Hillan, who will step down effective today after a successful 7-year tenure as a director of Zymeworks.
  • “Zymeworks is honored to welcome Dr. Cesano to our board of directors,” said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks.
  • She joins three other new directors appointed in 2023: Mr. Derek Miller, Mr. Carlos Campoy, and Dr. Nancy Davidson.”
    “The Zymeworks board of directors is sincerely grateful to Dr. Hillan for his dedicated service and significant contributions to the board.
  • Dr. Cesano was also appointed to serve as a member of the research and development committee and nominating and corporate governance committee of the board of directors.

23andMe Reports Third Quarter Fiscal 2024 Financial Results

Retrieved on: 
Wednesday, February 7, 2024
GSK plc, PGS, Pharmacokinetics, SAN, Growth, Net, Inflammation, Table, Investigational New Drug, Research, SITC, Genetics, NK, Society, Consumer, Patient, IND, African Americans, FDA, Database, Immunotherapy, Therapy, Total, Premium, Webcast, Cancer, 23andMe, GSK, Workforce, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the third quarter of fiscal year 2024 (FY24), which ended December 31, 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the third quarter of fiscal year 2024 (FY24), which ended December 31, 2023.
  • “The Company had a very productive third quarter, with meaningful strategic progress across all three business lines,” said Anne Wojcicki, Co-Founder & CEO of 23andMe.
  • Full year Adjusted EBITDA deficit is adjusted to be in the range of $185 to $180 million for fiscal year 2024.
  • 23andMe will host a conference call at 4:30 p.m. Eastern Time today, February 7, 2024, to discuss the financial results for Q3 FY2024 and report on business progress.

Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing

Retrieved on: 
Tuesday, February 6, 2024
Prostate cancer, Investigational New Drug, Cytokine, Immunotherapy, SITC, Clinical trial, NK, Society, Patient, IND, Good, Death, TSX, Allele, NKT, Therapy, Vaccine, Good manufacturing practice, HLA, Cancer, GMP, BCT

We are enthusiastic about commencing GMP manufacturing for our prostate cancer clinical candidate, continuing our efforts at transforming targeted cancer therapy via the introduction of potent personalized cellular cancer vaccines,” stated Dr. William V. Williams, BriaCell’s President and CEO.

Key Points: 
  • We are enthusiastic about commencing GMP manufacturing for our prostate cancer clinical candidate, continuing our efforts at transforming targeted cancer therapy via the introduction of potent personalized cellular cancer vaccines,” stated Dr. William V. Williams, BriaCell’s President and CEO.
  • “The successful development of this first candidate showcases our capacity to create novel cancer immunotherapies and advance them towards clinical application.
  • BriaCell genetically engineers cancer cell lines to produce cytokines and co-stimulatory factors that significantly increase immune stimulation compared to the unmodified (parent) cancer cell lines.
  • According to 2024 Cancer Facts & Figures , prostate cancer is projected to be the most common cancer among men in 2024.

Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts

Retrieved on: 
Monday, February 5, 2024
Injection, Serology, OS, Tumor microenvironment, Survival, Prostate cancer, Breast cancer, Immunotherapy, Pancreatic cancer, MD, PDAC, SITC, Enlightenment, Food and Drug Administration, Lung cancer, Society, Clinical trial, Therapy, Patient, Brain, Cancer, FDA, Biomarker, Trial of the century, Food, CADL, Fast track (FDA), CSO, Disease, Biology, Pancreatitis, Doctor of Philosophy, Valaciclovir, Conference, Pharmaceutical industry

“Candel is focused on delivering key value drivers to maximize the impact of its assets and to create substantial value to patients and other stakeholders.

Key Points: 
  • “Candel is focused on delivering key value drivers to maximize the impact of its assets and to create substantial value to patients and other stakeholders.
  • In 2023, we received Fast Track Designation from the FDA for CAN-2409, our most advanced product candidate, for both NSCLC and pancreatic cancer.
  • This platform is open for collaborations with external partners.”
    The Company's strategic prioritization of programs highlights Candel Therapeutics' commitment to operational excellence and efficiency.
  • This approach positions the Company for sustained success in the current dynamic market for new cancer therapeutics.

Elephas Announces $55 Million in Series C Funding

Retrieved on: 
Tuesday, January 23, 2024
Tao, Patient, SITC, Society, XMS Capital Partners, Cancer, Immunotherapy, Drug development, Biomarker

MADISON, Wis., Jan. 23, 2024 /PRNewswire/ -- Elephas Biosciences Corporation (Elephas), a private company, announced today that it has raised $55 million in Series C funding. Venture Investors Health Fund and State of Wisconsin Investment Board (SWIB) led the round. Continuing investments were made by Northpond Ventures, ARCH Ventures, Sands Capital, Moore Strategic Ventures, Tao Invest, and WARF Ventures. With this $55 million Series C funding, this brings the total raised by Elephas to $116.5 million.

Key Points: 
  • MADISON, Wis., Jan. 23, 2024 /PRNewswire/ -- Elephas Biosciences Corporation (Elephas), a private company, announced today that it has raised $55 million in Series C funding.
  • With this $55 million Series C funding, this brings the total raised by Elephas to $116.5 million.
  • Elephas is developing an oncology imaging diagnostics platform to predict response to immunotherapy using the latest advances in metabolic imaging.
  • "We remain intensely focused on our mission to improve care for cancer patients," stated Maneesh Arora, founder and CEO of Elephas.

ClearNote Health Announces New Proprietary Approach for Predicting Immunotherapy Treatment Response in Non-Small Cell Lung Cancer Using Only Blood

Retrieved on: 
Tuesday, January 16, 2024
Oncology, Health, Technology, Other Health, Artificial Intelligence, Biotechnology, Hope, Translational research, Translation, Prostate cancer, Patient, Biology, Research, SITC, DNA, Type 2 diabetes, PD-1, Nivolumab, Society, Cancer research, Nucleic acid thermodynamics, Immunotherapy, Risk, NSCLC, Plasma, Journal, Disease, Lung cancer, Biomarker, Pembrolizumab, Bayer, Pancreatic cancer, Pharmaceutical industry

The article, “ Plasma Cell-Free DNA Hydroxymethylation Profiling Reveals Anti-PD-1 Treatment Response and Resistance Biology in Non-Small Cell Lung Cancer ,” was published in the online issue of The Journal for ImmunoTherapy of Cancer, the official journal of the Society for Immunotherapy of Cancer (SITC) .

Key Points: 
  • The article, “ Plasma Cell-Free DNA Hydroxymethylation Profiling Reveals Anti-PD-1 Treatment Response and Resistance Biology in Non-Small Cell Lung Cancer ,” was published in the online issue of The Journal for ImmunoTherapy of Cancer, the official journal of the Society for Immunotherapy of Cancer (SITC) .
  • The comparison of plasma-derived cfDNA 5-hmC profiles revealed differences that distinguish patients responding to therapy from those not responding before and throughout treatment.
  • This underscores the value of 5hmC analysis for the measurement of treatment response biomarkers without the need for an invasive and potentially deadly tissue biopsy.
  • A recently published study in Cancer Research, “ The 5-Hydroxymethylcytosine Landscape of Prostate Cancer ,” showed the utility of ClearNote Health’s platform in marking epigenetic activation in prostate cancer and identifying hallmarks of prostate cancer progression.